Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот ресурс: http://elar.urfu.ru/handle/10995/111816
Название: Problems of Selecting an Anticoagulant for Secondary Stroke Prevention in Patients with Atrial Fibrillation
Авторы: Gusev, V. V.
Lvova, O. A.
Shamalov, N. A.
Дата публикации: 2021
Издатель: Silicea-Poligraf
Silicea - Poligraf, LLC
Библиографическое описание: Gusev V. V. Problems of Selecting an Anticoagulant for Secondary Stroke Prevention in Patients with Atrial Fibrillation / V. V. Gusev, O. A. Lvova, N. A. Shamalov. — DOI 10.1016/j.rinp.2021.104336 // Cardiovascular Therapy and Prevention (Russian Federation). — 2021. — Vol. 20. — Iss. 6. — P. 78-83. — 3044.
Аннотация: The article describes the urgent problem of ischemic stroke prevention in patients with atrial fibrillation. It is proved that ischemic stroke in combination with AF is the most severe in terms of developing stable motor and speech disorders and disability. The frail older patients, as well as patients with swallowing disorders and reduced medical adherence present a special problem from this point of view. The most famous clinical studies on secondary prevention of cardioembolic stroke are RE-LY, ROCKET-AF, and ARISTOTLE. Based on subanalyses of randomized controlled trials, direct oral anticoagulants demonstrated a favorable efficacy profile in patients with atrial fibrillation and stroke/ transient ischemic attack, but the level of knowledge on each of them remained different. A number of advantages of rivaroxaban for primary and secondary prevention of stroke in patients with atrial fibrillation, including the elderly and patients with cognitive impairments and swallowing disorders, have been demonstrated. © 2021 Vserossiiskoe Obshchestvo Kardiologov. All rights reserved.
Ключевые слова: ATRIAL FIBRILLATION
DIRECT ORAL ANTICOAGULANTS
ISCHEMIC STROKE
SECONDARY PREVENTION
ANTICOAGULANT AGENT
RIVAROXABAN
ARTICLE
ATRIAL FIBRILLATION
CARDIOEMBOLIC STROKE
COGNITIVE DEFECT
DRUG EFFICACY
DYSPHAGIA
HUMAN
ISCHEMIC STROKE
MOTOR DYSFUNCTION
PROPHYLAXIS
RANDOMIZED CONTROLLED TRIAL (TOPIC)
SPEECH DISORDER
TRANSIENT ISCHEMIC ATTACK
URI: http://elar.urfu.ru/handle/10995/111816
Условия доступа: info:eu-repo/semantics/openAccess
Идентификатор РИНЦ: 46668097
Идентификатор SCOPUS: 85118292019
Идентификатор PURE: 23917728
ISSN: 1728-8800
DOI: 10.1016/j.rinp.2021.104336
Сведения о поддержке: Relationships and Activities. This publication was supported by AO Bayer (PPM_RIVRU00581).
Располагается в коллекциях:Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC

Файлы этого ресурса:
Файл Описание РазмерФормат 
2-s2.0-85118292019.pdf175,57 kBAdobe PDFПросмотреть/Открыть


Все ресурсы в архиве электронных ресурсов защищены авторским правом, все права сохранены.